Genentech's Actemra gains FDA approval for rheumatoid arthritis

01/10/2010 | San Francisco Chronicle

The FDA approved Genentech's Actemra, the only rheumatoid arthritis drug that targets the interleukin-6 protein, which plays a role in joint inflammation. The treatment is expected to benefit patients who do not respond to Remicade, Humira or Enbrel, which target an inflammatory protein called tumor necrosis factor-alpha.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR